Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

Trial Profile

Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2012 Planned end date changed from 1 Jan 2012 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 10 May 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 29 Jul 2010 Planned end date changed from Oct 2006 to Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top